Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients

NCT02201459 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Nilotinib (Tasigna ®), capsules of 150 mg
DRUG: Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)

Sponsor

Hospices Civils de Lyon

Collaborators

[object Object]